January 10, 2022
Maze Therapeutics
Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases
January 10, 2022
Magenta Therapeutics
Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
January 10, 2022
Fulcrum Therapeutics
Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases
January 04, 2022
Allena Pharmaceuticals
Allena Pharmaceuticals Provides Clinical and Corporate Update
January 04, 2022
Fulcrum Therapeutics
Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer